Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - doxorubicin hydrochloride 2 mg/ml;  ;  ;   - solution for injection - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml       excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

cell pharm gmbh - doxorubicin hydrochloride - solution for injection - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - adriamycin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms? tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin?s and non-hodgkin?s type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. adriamycin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder (tis, t1, t2).

Armenia - angielski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - doxorubicin (doxorubicin hydrochloride) - concentrate for solution for infusion - 2mg/ml

Armenia - angielski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - doxorubicin (doxorubicin hydrochloride) - concentrate for solution for infusion - 2mg/ml

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - adriamycin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. adriamycin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin hydrochloride has been used successfully both as a single agent and also in combination with other approved cancer chemotherapeutic agents to produce regression in neoplastic conditions such as: acute lymphoblastic leukaemia, acute myeloblastic leukaemia, wilms? tumour, neuroblastomas, soft tissue sarcomas, bone sarcomas, breast cancer, gynecologic carcinomas, testicular carcinomas, bronchogenic carcinoma, hodgkin?s and non-hodgkin?s lymphoma, thyroid carcinoma, bladder carcinomas, head and neck cancer and gastric cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin (doxorubicin hydrochloride) has been used successfully both as a single agent and also in combination with other approved cancer chemotherapeutic agents to produce regression in neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms? tumor, neuroblastomas, soft tissue sarcomas, bone sarcomas, breast carcinoma, gynecologic carcinomas, testicular carcinomas, bronchogenic carcinoma, hodgkin's disease, non-hodgkin's lymphoma, thyroid carcinoma, bladder carcinomas, squamous cell carcinoma of the head and neck, and gastric carcinoma